Is Kaletra monotherapy enough?
cet article est disponible en franais Report from The XV International AIDS Conference, July 11–16, 2004 At the 1996 International AIDS Conference in Vancouver, it became clear that therapy with at least three different anti-HIV drugs was able to reduce the risk of life-threatening infections and prolong survival—something that had never happened in the history of HIV/AIDS treatment. In the time before this development, the accepted standard of care was one or two of the following drugs: AZT (zidovudine, Retrovir) ddI (didanosine, Videx) 3TC (lamivudine, Epivir) d4T (stavudine, Zerit) Therapy with just one drug at a time was called monotherapy, and it quickly led to the development of drug resistance. Given this history of treatment, it was somewhat disconcerting to see posters and presentations about monotherapy at this year’s International AIDS Conference in Bangkok. Perhaps now, eight years after the Vancouver conference, some things have changed that led doctors to reconsider the r
